80 related articles for article (PubMed ID: 25929584)
1. Syntheses of some α-cyclic tripeptides as potential inhibitors for HMG-CoA Reductase.
Chakraborty S; Lin SH; Shiuan D; Tai DF
Amino Acids; 2015 Aug; 47(8):1495-505. PubMed ID: 25929584
[TBL] [Abstract][Full Text] [Related]
2. Recognized sequence and conformation in design of linear peptides as a competitive inhibitor for HMG-CoA reductase.
Pak VV; Koo M; Yun L; Kwon DY
J Mol Recognit; 2007; 20(3):197-203. PubMed ID: 17486664
[TBL] [Abstract][Full Text] [Related]
3. Exploration of natural product ingredients as inhibitors of human HMG-CoA reductase through structure-based virtual screening.
Lin SH; Huang KJ; Weng CF; Shiuan D
Drug Des Devel Ther; 2015; 9():3313-24. PubMed ID: 26170618
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and docking of highly hypolipidemic agents: Schizosaccharomyces pombe as a new model for evaluating alpha-asarone-based HMG-CoA reductase inhibitors.
Argüelles N; Sánchez-Sandoval E; Mendieta A; Villa-Tanaca L; Garduño-Siciliano L; Jiménez F; Cruz Mdel C; Medina-Franco JL; Chamorro-Cevallos G; Tamariz J
Bioorg Med Chem; 2010 Jun; 18(12):4238-48. PubMed ID: 20576575
[TBL] [Abstract][Full Text] [Related]
5. Binding effect and design of a competitive inhibitory peptide for HMG-CoA reductase through modeling of an active peptide backbone.
Pak VV; Koo M; Kim MJ; Yun L; Kwon DY
Bioorg Med Chem; 2008 Feb; 16(3):1309-18. PubMed ID: 17977732
[TBL] [Abstract][Full Text] [Related]
6. Natural Inhibitors of HMG-CoA Reductase-An Insilico Approach Through Molecular Docking and Simulation Studies.
Suganya S; Nandagopal B; Anbarasu A
J Cell Biochem; 2017 Jan; 118(1):52-57. PubMed ID: 27216569
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and highly potent hypolipidemic activity of alpha-asarone- and fibrate-based 2-acyl and 2-alkyl phenols as HMG-CoA reductase inhibitors.
Mendieta A; Jiménez F; Garduño-Siciliano L; Mojica-Villegas A; Rosales-Acosta B; Villa-Tanaca L; Chamorro-Cevallos G; Medina-Franco JL; Meurice N; Gutiérrez RU; Montiel LE; Cruz Mdel C; Tamariz J
Bioorg Med Chem; 2014 Nov; 22(21):5871-82. PubMed ID: 25311563
[TBL] [Abstract][Full Text] [Related]
8. Use of virtual screening, flexible docking, and molecular interaction fields to design novel HMG-CoA reductase inhibitors for the treatment of hypercholesterolemia.
da Silva VB; Taft CA; Silva CH
J Phys Chem A; 2008 Mar; 112(10):2007-11. PubMed ID: 18044855
[TBL] [Abstract][Full Text] [Related]
9. Molecular docking of the highly hypolipidemic agent alpha-asarone with the catalytic portion of HMG-CoA reductase.
Medina-Franco JL; López-Vallejo F; Rodríguez-Morales S; Castillo R; Chamorro G; Tamariz J
Bioorg Med Chem Lett; 2005 Feb; 15(4):989-94. PubMed ID: 15686898
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in silico studies of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitory activity of the cowpea Gln-Asp-Phe peptide.
Silva MBCE; Souza CADC; Philadelpho BO; Cunha MMND; Batista FPR; Silva JRD; Druzian JI; Castilho MS; Cilli EM; Ferreira ES
Food Chem; 2018 Sep; 259():270-277. PubMed ID: 29680054
[TBL] [Abstract][Full Text] [Related]
11. Molecular Docking, Synthesis And Biological Evaluation Of Ergosteryl-Ferulate As A Hmg-Coa Reductase Inhibitor.
Aziz S; Elfahmi -; Soemardji AA; Sukrasno -
Pak J Pharm Sci; 2020 May; 33(3):997-1003. PubMed ID: 33191223
[TBL] [Abstract][Full Text] [Related]
12. Design of a highly potent inhibitory peptide acting as a competitive inhibitor of HMG-CoA reductase.
Pak VV; Koo M; Kwon DY; Yun L
Amino Acids; 2012 Nov; 43(5):2015-25. PubMed ID: 22451276
[TBL] [Abstract][Full Text] [Related]
13. Peptide fragmentation as an approach in modeling of an active peptide and designing a competitive inhibitory peptide for HMG-CoA reductase.
Pak VV; Koo M; Kwon DY; Shakhidoyatov KM; Yun L
Bioorg Med Chem; 2010 Jun; 18(12):4300-9. PubMed ID: 20494585
[TBL] [Abstract][Full Text] [Related]
14. Serine/threonine ligation for natural cyclic peptide syntheses.
Lee CL; Lam HY; Li X
Nat Prod Rep; 2015 Sep; 32(9):1274-9. PubMed ID: 26023909
[TBL] [Abstract][Full Text] [Related]
15. Automated enzyme inhibition assay method for the determination of atorvastatin-derived HMG-CoA reductase inhibitors in human plasma using radioactivity detection.
Valesky RJ; Liu L; Musson DG; Zhao JJ
J Pharmacol Toxicol Methods; 2008; 57(1):61-9. PubMed ID: 17651990
[TBL] [Abstract][Full Text] [Related]
16. Discovery of pyrrole-based hepatoselective ligands as potent inhibitors of HMG-CoA reductase.
Bratton LD; Auerbach B; Choi C; Dillon L; Hanselman JC; Larsen SD; Lu G; Olsen K; Pfefferkorn JA; Robertson A; Sekerke C; Trivedi BK; Unangst PC
Bioorg Med Chem; 2007 Aug; 15(16):5576-89. PubMed ID: 17560788
[TBL] [Abstract][Full Text] [Related]
17. Antihyperlipidemic studies of newly synthesized phenolic derivatives: in silico and in vivo approaches.
Aqeel MT; Ur-Rahman N; Khan AU; Ashraf Z; Latif M; Rafique H; Rasheed U
Drug Des Devel Ther; 2018; 12():2443-2453. PubMed ID: 30127594
[TBL] [Abstract][Full Text] [Related]
18. Peptide inhibitors of human HMG-CoA reductase as potential hypocholesterolemia agents.
Lin SH; Chang DK; Chou MJ; Huang KJ; Shiuan D
Biochem Biophys Res Commun; 2015 Jan; 456(1):104-9. PubMed ID: 25446106
[TBL] [Abstract][Full Text] [Related]
19. Three-dimensional quantitative structure (3-D QSAR) activity relationship studies on imidazolyl and N-pyrrolyl heptenoates as 3-hydroxy-3-methylglutaryl-CoA reductase (HMGR) inhibitors by comparative molecular similarity indices analysis (CoMSIA).
Thilagavathi R; Kumar R; Aparna V; Sobhia ME; Gopalakrishnan B; Chakraborti AK
Bioorg Med Chem Lett; 2005 Feb; 15(4):1027-32. PubMed ID: 15686906
[TBL] [Abstract][Full Text] [Related]
20. Peptide design of a competitive inhibitor for HMG-CoA reductase based on statin structure.
Pak VV; Kim SH; Koo M; Lee N; Shakhidoyatov KM; Kwon DY
Biopolymers; 2006; 84(6):586-94. PubMed ID: 16886212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
